tirzepatide vs semaglutide benefits risks caused roughly half as many patients to stop treatment because of gastrointestinal side effects as semaglutide. In the first major head-to-head obesity trial, GI side effects caused treatment discontinuation in: Tirzepatide Stopping GLP-1 drugs can quickly

HIF- has three isoforms, HIF-1, HIF-2, and HIF-3

The combined oral formulation of ebselen/allopurinol reduced multiple cisplatin toxicities in rat breast and ovarian cancers (Lynch et al., 2005)

Accelerometer-derived sleep onset timing and cardiovascular disease incidence: a UK Biobank cohort study

Cost-benefit at scale: If millions use retatrutide for years, do the cardiovascular and diabetes prevention benefits outweigh the side effect burden and $15,00018,000 annual cost

The Lancet said in an article in February: The practice of microdosing drugs is not new, but there is no evidence that it works for obesity. Ann Marie Defnet, a bariatric surgeon at Northwell Health, New York states largest healthcare provider, says in its health publication the Well: Clinical trials are where we figure out whether a treatment is both effective and safe

For same-day availability, please DM us on Instagram @bianca_clinic_tokyo